| Marlecia Lanei Lambeth, PA | |
|
4320 Seminary Rd, Alexandria, VA 22304-1535 | |
| (703) 799-1688 | |
| (703) 799-4092 |
| Full Name | Marlecia Lanei Lambeth |
|---|---|
| Gender | Female |
| Speciality | Physician Assistant |
| Experience | 13 Years |
| Location | 4320 Seminary Rd, Alexandria, Virginia |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1356628747 | NPI | - | NPPES |
| Facility Name | Location | Facility Type |
|---|---|---|
| Inova Alexandria Hospital | Alexandria, VA | Hospital |
| Inova Fairfax Hospital | Falls church, VA | Hospital |
| Doctors' Community Hospital | Lanham, MD | Hospital |
| Inova Mount Vernon Hospital | Alexandria, VA | Hospital |
| University Of Md Charles Regional Medical Center | La plata, MD | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Inova Health Care Services | 2466351093 | 1725 |
| Luminis Health Medical Group, Llc | 2860447315 | 431 |
News Archive
Researchers identify sleep as a problem in patients with stroke, and highlight the need to give greater consideration to sleep in stroke care, and in particular stroke rehabilitation.
Mutations in the presenilin-1 gene are the most common cause of inherited, early-onset forms of Alzheimer's disease. In a new study, published in Neuron, scientists replaced the normal mouse presenilin-1 gene with Alzheimer's-causing forms of the human gene to discover how these genetic changes may lead to the disorder.
The Critical Care Recovery Center care model - the nation's first collaborative care concept focusing on the extensive cognitive, physical and psychological recovery needs of intensive care unit survivors - decreases the likelihood of serious illness after discharge from an ICU, according to a new study from the Regenstrief Institute and the Indiana University schools of medicine and nursing.
A new Boston University School of Public Health study of the first four months of America's coronavirus epidemic, published in the journal Nature Human Behaviour, shows that physical distancing (also called "social distancing") policies had little effect.
The Muscular Dystrophy Association today announced it has awarded $1.4 million in new research funding to the biopharmaceutical firm Repligen of Waltham, Mass., to complete the preclinical work needed to begin human clinical trials of a promising therapeutic compound for spinal muscular atrophy (SMA).
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Marlecia Lanei Lambeth, PA Po Box 11553, Newark, NJ 07101-4553 Ph: (240) 965-4413 | Marlecia Lanei Lambeth, PA 4320 Seminary Rd, Alexandria, VA 22304-1535 Ph: (703) 799-1688 |
News Archive
Researchers identify sleep as a problem in patients with stroke, and highlight the need to give greater consideration to sleep in stroke care, and in particular stroke rehabilitation.
Mutations in the presenilin-1 gene are the most common cause of inherited, early-onset forms of Alzheimer's disease. In a new study, published in Neuron, scientists replaced the normal mouse presenilin-1 gene with Alzheimer's-causing forms of the human gene to discover how these genetic changes may lead to the disorder.
The Critical Care Recovery Center care model - the nation's first collaborative care concept focusing on the extensive cognitive, physical and psychological recovery needs of intensive care unit survivors - decreases the likelihood of serious illness after discharge from an ICU, according to a new study from the Regenstrief Institute and the Indiana University schools of medicine and nursing.
A new Boston University School of Public Health study of the first four months of America's coronavirus epidemic, published in the journal Nature Human Behaviour, shows that physical distancing (also called "social distancing") policies had little effect.
The Muscular Dystrophy Association today announced it has awarded $1.4 million in new research funding to the biopharmaceutical firm Repligen of Waltham, Mass., to complete the preclinical work needed to begin human clinical trials of a promising therapeutic compound for spinal muscular atrophy (SMA).
› Verified 5 days ago